Multiplex Mass Spectrometric Immunoassays Will Improve Cancer Diagnosis

Intrinsic Bioprobes Inc. (Tempe, AZ, USA) has entered into a contract with the National Cancer Institute to develop effective technologies for accurate measurement of low abundance cancer-related proteins and peptides. The total cost of the two and a half years contract is US $1,276,360, out of which $1,130,272 is Federal money provided by the NCI, and $146,088 is the contractor's share provided by Intrinsic Bioprobes Inc.

Intrinsic Bioprobes Inc. is a privately held biotechnology company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. Mass Spectrometric Immunoassay (MSIA) is a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high throughput analysis of proteins from complex biological matrices. Bioreactive Mass Spectrometer Probes (BRPT) devices provide rapid, sensitive, and accurate protein characterization.

Dobrin Nedelkov, Ph.D., scientific director of Intrinsic Bioprobes commented, "The application of proteomics tools in clinical setting lags far behind their use in basic science and drug discovery. The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables single step detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics approaches."

Related Links:
Intrinsic Bioprobes Inc.